Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.

British journal of haematology - 1 Jan 2016

Baumann Tycho, Delgado Julio, Santacruz Rodrigo, Martínez-Trillos Alejandra, Rozman María, Aymerich Marta, López Cristina, Costa Dolors, Carrió Anna, Villamor Neus, Montserrat Emili

Abstract excerpt

We investigated CD49d (also termed ITGA4) expression and its biological and clinical correlations in 415 patients with chronic lymphocytic leukaemia. CD49d expression was stable over the course of the disease. A high expression of CD49d (>30%) was found in 142/415 (34%) patients and was associated with progressive disease (advanced clinical stage, high serum lactate dehydrogenase or β2 -microglobulin levels; all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Heavy Chains

Share to Kaplan-Meier Estimate

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Lymphocyte Count

Share to Prognosis

Share to Time Factors

Source

Identifiers

PMID: 26559905
DOI: 10.1111/bjh.13788

Genes

ITGA4
ZAP70
NOTCH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.PMID 26559905Read ↗

CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.Semantic proximity Read ↗

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.Semantic proximity Read ↗

CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.Semantic proximity Read ↗

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.Semantic proximity Read ↗

CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevanceSemantic proximity Read ↗

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanismSemantic proximity Read ↗

An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted TherapySemantic proximity Read ↗

Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.Semantic proximity Read ↗

Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.Semantic proximity Read ↗

Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.Semantic proximity Read ↗

High CXCR3 on Leukemic Cells Distinguishes IgHV mut from IgHV unmut in Chronic Lymphocytic Leukemia: Evidence from CD5high and CD5low Clones.Semantic proximity Read ↗

CD6 expression is an independent predictor of time to first treatment in chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.